Canum is currently in development with upcoming clinical trials. Join our waitlist for updates.
Precision health science for dogs

More comfort.
Better years together.

We're developing high-potency, precision probiotics and an easy-to-use app platform designed to support skin, coat, and digestive health in dogs of all ages. Clinical evaluation is currently underway.

Join the Waitlist Learn More
Clinical evaluation underway
The Root Cause

It's not just allergies.
It's gut-driven imbalance.

When your dog's microbiome is out of balance, it can influence signals throughout their body showing up as the day-to-day things you notice: paw licking, skin discomfort, and more frequent scratching.

Canum is building a bio-digital platform that combines a high potency probiotic formulation in development to support the gut and immune system alongside a companion mobile app to help dog parents track their dog's health over time.

Paw irritation

Constant focus on paws can be a sign of underlying gut and immune imbalance, not just environmental irritants.

Skin discomfort

When harmful bacteria dominate the gut, it may influence pathways that affect the skin barrier and overall comfort.

Areas of redness

Those sensitive patches can be linked to changes in the immune system that we're working to better understand through ongoing research.

Our Approach

Health from within.
Designed to support.

Canum's precision formula is being evaluated for its ability to support balanced microbiome function with strains chosen for their potential to support healthy inflammatory balance. It is not intended to diagnose, treat, cure, or prevent any disease.

Designed to support immune balance and inflammatory responses

Created to strengthen the connection from the inside out with targeted nutrients

Under evaluation to support healthy aging with customized formulations

Canum powder

Canum Daily

Prototype Product Design

How It Works

Simple routine.
A science-guided approach.

We're evaluating a daily high-potency probiotic and a companion mobile app for their potential to support gut balance and skin in dogs.

1

Formulation

A high-potency probiotic formulation designed to support gut and skin barrier function, currently under evaluation.

2

App + tracking

Mobile app designed to help owners track signals (itching, stool quality, coat changes) and utilize cutting-edge AI models to generate data insights to share with their vet.

3

Validation

We're running controlled studies to measure outcomes. Results will be shared and published as studies complete.

Product features and claims are subject to change based on trial results and regulatory review.

THE SCIENCE

Built on human clinical research.
Now being evaluated in dogs.

The probiotic strains behind Canum were originally studied in human clinical trials for gut and immune-related outcomes. Our founder has firsthand experience in developing and patenting novel synbiotic formulations for inflammatory conditions. Canum will adapt this scientific foundation in humans to be utilized in dogs, and controlled studies are upcoming. The underlying research demonstrated a three-part mechanism: strengthening gut barrier integrity, modulating immune responses, and reducing inflammatory markers, a clear pathway with direct relevance to canine skin, digestive, and immune health.

HUMAN CLINICAL RESEARCH
7 peer-reviewed publications

The probiotic strains behind our formulation were validated in humans across 9 peer-reviewed studies to demonstrate their safety, tolerability, efficacy, and mode of action. Research was conducted at institutions including Harvard-affiliated research centers and international university labs.

FOUNDER-LED SCIENCE
9 issued U.S. patents

Our founder invented and patented novel synbiotic formulations for inflammatory and age-related conditions in humans with 9 issued U.S. patents and 25+ filings across multiple patent families covering composition of matter and methods of use.

CANINE STUDIES
Controlled trials with dogs

Soon, we'll be running pilot evaluations to measuring owner-reported outcomes of skin comfort, digestive stability, and coat quality. Additional clinical studies with randomized controlled trials (RCT) will be conducted to evaluate the efficacy of the probiotic strains in dogs.

Development status
Strain selection & formulation
Complete
Safety & tolerability validation
In Progress
Canine clinical evaluation
Upcoming
Launch
Upcoming

Canum's products are in development. These statements have not been evaluated by the FDA. The products are not intended to diagnose, treat, cure, or prevent any disease.

The Team

Rigor and passion to create science.
Meet our people.

Gerardo V. Toledo, Founder & CEO
Founder & CEO

Gerardo V. Toledo

PhD, Marine Biology, Scripps Institution of Oceanography at UC San Diego
MBA, Sloan School of Management at MIT

Canum was co-founded by Gerardo V. Toledo, building on his entrepreneurial journey developing science-driven synbiotic medical foods to address inflammatory conditions in humans.

Drawing on years of clinical product development and a lifelong commitment to preventive health, Canum is now translating that foundation to dogs with a bio-digital platform currently in development. Upcoming studies will evaluate how precision probiotics and health tracking can support healthy aging in dogs. Canum combines the rigorous science from Gerardo's research background with a business concept shaped at MIT, the premier launching pad for breakthrough technology innovation and disciplined entrepreneurship.

Scientific & Strategic Advisors

Nic Roth

Software Engineering Advisor
Early Access

Launching soon

Canum is in development and not yet commercially available. Join the waitlist to be first in line for early access and trial updates.

Join the Waitlist
Joining the waitlist is free and used only to share development and clinical trial updates.
No purchase required.

Frequently asked questions

A quick look at Canum's current development and progress to address the most common questions we get about our product and company.

Canum is in early product development with clinical studies upcoming.
Canum is targeting a staged launch after trials complete and we review results.
We measure owner-reported outcomes (itching, coat quality, stool quality) and other study-defined endpoints.
Yes. We intend to share and publish results in reputable peer-reviewed journalsSummaries and the full methodology will be shared as our studies conclude.
No. Canum is being developed as a health support product. It is not intended to diagnose, treat, cure, or prevent any disease.